GlassScriptPhysician profile
Mohan Singh Charan
NPI 1982609335
$539.09
in general payments reported to CMS, 2019-2025
14 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $153 · 2022: $50.39 · 2023: $47.45 · 2024: $64.36 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $104.05 | 2022-2025 | Rinvoq |
| Paratek Pharmaceuticals, INC. | $76.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.98 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $31.16 | 2019 | |
| Genzyme Corporation | $31.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $29.93 | 2025 | Iqirvo |
| Celgene Corporation | $29.51 | 2022 | |
| Redhill Biopharma INC. | $22.35 | 2021 | |
| Medtronic, INC. | $21.42 | 2023 | Gi Genius |
| Braintree Laboratories, INC. | $20.22 | 2024 | Suflave |
| Janssen Biotech, INC. | $20.10 | 2024 | Tremfya |
| Mauna Kea Technologies, INC. | $14.92 | 2021 | |
| Merck Sharp & Dohme LLC | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Charan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.